Shaowei Wu1, Jiali Han2, Wen-Qing Li3, Abrar A Qureshi4. 1. Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island2Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 2. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts4Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis5Melvin. 3. Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island. 4. Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island2Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts3Channing Division of Network Medicine, Department.
Abstract
IMPORTANCE: Individuals with psoriasis have an elevated risk of hypertension, and antihypertensive medications, especially β-blockers, have been linked to psoriasis development. However, the association of prior existing hypertension and antihypertensive medications with risk of incident psoriasis has not been assessed using prospective data. OBJECTIVE: To evaluate the association of hypertension and antihypertensive medications with risk of psoriasis. DESIGN, SETTING, AND PARTICIPANTS: We performed a prospective cohort study (June 1, 1996, to June 1, 2008) of 77 728 US women from the Nurses' Health Study who provided biennially updated data on hypertension and antihypertensive medications. MAIN OUTCOMES AND MEASURES: Physician-diagnosed psoriasis. RESULTS: A total of 843 incident psoriasis cases were documented during 1 066 339 person-years of follow-up. Compared with normotensive women, women with a hypertension duration of 6 years or more were at a higher risk of developing psoriasis (hazard ratio [HR], 1.27; 95% CI, 1.03-1.57). In stratified analysis, the risk of psoriasis was higher among hypertensive women without medication use (HR, 1.49; 95% CI, 1.15-1.92) and among hypertensive women with current medication use (HR, 1.31; 95% CI, 1.10-1.55) when compared with normotensive participants without medication use. Compared with women who never used β-blockers, the multivariate HRs for psoriasis for women who regularly used β-blockers were 1.11 (95% CI, 0.82-1.51) for 1 to 2 years of use, 1.06 (95% CI, 0.79-1.40) for 3 to 5 years of use, and 1.39 (95% CI, 1.11-1.73) for 6 years or more of use (P for trend = .009). No association was found between use of other individual antihypertensive drugs and risk of psoriasis. CONCLUSIONS AND RELEVANCE: Long-term hypertensive status is associated with an increased risk of psoriasis. Long-term regular use of β-blockers may also increase the risk of psoriasis.
IMPORTANCE: Individuals with psoriasis have an elevated risk of hypertension, and antihypertensive medications, especially β-blockers, have been linked to psoriasis development. However, the association of prior existing hypertension and antihypertensive medications with risk of incident psoriasis has not been assessed using prospective data. OBJECTIVE: To evaluate the association of hypertension and antihypertensive medications with risk of psoriasis. DESIGN, SETTING, AND PARTICIPANTS: We performed a prospective cohort study (June 1, 1996, to June 1, 2008) of 77 728 US women from the Nurses' Health Study who provided biennially updated data on hypertension and antihypertensive medications. MAIN OUTCOMES AND MEASURES: Physician-diagnosed psoriasis. RESULTS: A total of 843 incident psoriasis cases were documented during 1 066 339 person-years of follow-up. Compared with normotensive women, women with a hypertension duration of 6 years or more were at a higher risk of developing psoriasis (hazard ratio [HR], 1.27; 95% CI, 1.03-1.57). In stratified analysis, the risk of psoriasis was higher among hypertensivewomen without medication use (HR, 1.49; 95% CI, 1.15-1.92) and among hypertensivewomen with current medication use (HR, 1.31; 95% CI, 1.10-1.55) when compared with normotensive participants without medication use. Compared with women who never used β-blockers, the multivariate HRs for psoriasis for women who regularly used β-blockers were 1.11 (95% CI, 0.82-1.51) for 1 to 2 years of use, 1.06 (95% CI, 0.79-1.40) for 3 to 5 years of use, and 1.39 (95% CI, 1.11-1.73) for 6 years or more of use (P for trend = .009). No association was found between use of other individual antihypertensive drugs and risk of psoriasis. CONCLUSIONS AND RELEVANCE: Long-term hypertensive status is associated with an increased risk of psoriasis. Long-term regular use of β-blockers may also increase the risk of psoriasis.
Authors: Arnon D Cohen; Dan Y Bonneh; Haim Reuveni; Daniel A Vardy; Lechaim Naggan; Sima Halevy Journal: Acta Derm Venereol Date: 2005 Impact factor: 4.437
Authors: Dorothea M Sommer; Stefan Jenisch; Michael Suchan; Enno Christophers; Michael Weichenthal Journal: Arch Dermatol Res Date: 2006-09-22 Impact factor: 3.017
Authors: Joel M Gelfand; Erica D Dommasch; Daniel B Shin; Rahat S Azfar; Shanu K Kurd; Xingmei Wang; Andrea B Troxel Journal: J Invest Dermatol Date: 2009-05-21 Impact factor: 8.551